Joshua J. Meeks, MD, PhD, explains how enfortumab vedotin plus pembrolizumab is reshaping organ preservation in MIBC.
|Videos|May 25, 2017
Dr. Badani on the Benefits of Robotic Surgery for Kidney Cancer
Author(s)Ketan K. Badani, MD
Ketan K. Badani, MD, professor of Urology at Mount Sinai Hospital, discusses the benefits of performing a partial robotic nephrectomy for patients with kidney cancer.
Advertisement
Ketan K. Badani, MD, professor of Urology at Mount Sinai Hospital, discusses the benefits of performing a partial robotic nephrectomy for patients with kidney cancer.
Having a minimally invasive surgery gives patients a quicker recovery time with less pain involved, explains Badani.
Additionally, the surgery is able to protect normal kidney function, which benefits the kidney over a longer period of time, states Badani.
Advertisement
Related to this article
Experts break down key kidney cancer data and trends from the 2026 ESMO Congress.
Praful Ravi, MB, BChir, MRCP, discusses the LASER futility readout, PSMA heterogeneity in clear cell RCC, and next steps for radiopharmaceuticals.
Daniel Heng, MD, MPH, FRCPC, discusses data from LITESPARK-011, second-line RCC sequencing, and managing belzutifan-associated anemia and hypoxia.
Advertisement
Advertisement
Trending on OncLive
1
VGX-3100 Elicits Regression and Clearance in HPV-16/18–Associated Cervical HSILs
2
EVX-01 Plus Pembrolizumab Yields Neoantigen-Specific T-Cell Responses in Advanced Melanoma
3
Zanidatamab, CLDN18.2-Directed ADCs, Ivonescimab, and KRAS Inhibitor Data Headline Key GI Cancer Findings From ESMO 2026
4
BCG-Unresponsive NMIBC Treatment Selection Requires Balancing Durability, Toxicity, and Patient Priorities
5